TL1A inhibitors have shown promise in mouse models for multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA), leading to further research characterizing TL1A’s role in inflammatory diseases to better anticipate potential side effects (32). This evidence concerns the gene TNFSF15 and multiple sclerosis.